- Home
- Publications
- Publication Search
- Publication Details
Title
Tebentafusp: First Approval
Authors
Keywords
-
Journal
DRUGS
Volume 82, Issue 6, Pages 703-710
Publisher
Springer Science and Business Media LLC
Online
2022-04-02
DOI
10.1007/s40265-022-01704-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 1014P Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in previously untreated patients with metastatic uveal melanoma
- (2021) A.K.S. Salama et al. ANNALS OF ONCOLOGY
- 1772P Demonstration of T cell redirection and immune activation in skin rash following tebentafusp treatment
- (2021) R. Stäger et al. ANNALS OF ONCOLOGY
- 1018P Characterization of liver function tests following tebentafusp in phase III randomized trial comparing tebentafusp with investigator’s choice in first line metastatic uveal melanoma (mUM)
- (2021) B. Chmielowski et al. ANNALS OF ONCOLOGY
- Characterization of liver function tests (LFTs) following tebentafusp (tebe) in previously treated (2L+) metastatic uveal melanoma (mUM) patients (pts).
- (2021) Takami Sato et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM).
- (2021) Richard D. Carvajal et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
- (2021) Paul Nathan et al. NEW ENGLAND JOURNAL OF MEDICINE
- 546 Results from Phase Ib study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)
- (2021) Omid Hamid et al. Journal for ImmunoTherapy of Cancer
- 538 Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp
- (2021) Joseph Sacco et al. Journal for ImmunoTherapy of Cancer
- Gp-100 as a Novel Therapeutic Target in Uveal Melanoma
- (2021) Daniel Martinez-Perez et al. Cancers
- Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma
- (2020) Mark R. Middleton et al. CLINICAL CANCER RESEARCH
- Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives
- (2020) Matías Chacón et al. Cancers
- 64MO A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM)
- (2020) J.J. Sacco et al. ANNALS OF ONCOLOGY
- Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma
- (2019) Bertil E. Damato et al. Cancers
- Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: Overall survival findings.
- (2018) Takami Sato et al. JOURNAL OF CLINICAL ONCOLOGY
- Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells
- (2017) Caroline Boudousquie et al. IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More